8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 28, 2026·SEC
Pacira BioSciences, Inc.(PCRX)Earnings, Financials & Key Ratios
PCRX•NASDAQ
$23.69
$932M mkt cap·148.1× P/E·Price updated May 6, 2026
AboutPacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Show more
- Revenue$726M+3.6%
- EBITDA$124M+2196.4%
- Net Income$7M+107.1%
- EPS (Diluted)0.16+107.4%
- Gross Margin79.39%+4.9%
- EBITDA Margin17.12%+2115.8%
- Operating Margin4.58%+143.8%
- Net Margin0.97%+106.8%
- ROE0.96%+107.9%
- ROIC2.35%+152.1%
- Debt/Equity0.66-20.1%
- Interest Coverage2.16+171.9%
PCRX Key Insights
Pacira BioSciences, Inc. (PCRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 9/9
- ✓FCF machine: 18.8% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 11.1%
- ✓Share count reduced 2.6% through buybacks
✗Weaknesses
- ✗Profits declining 45.4% over 5 years
- ✗Thin 5Y average net margin of 0.6%
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PCRX Price & Volume
Pacira BioSciences, Inc. (PCRX) stock price & volume — 10-year historical chart
Loading chart...
PCRX Growth Metrics
Pacira BioSciences, Inc. (PCRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.3%
5 Years11.07%
3 Years2.89%
TTM4.57%
Profit CAGR
10 Years14.25%
5 Years-45.44%
3 Years-23.82%
TTM108.97%
EPS CAGR
10 Years14.87%
5 Years-45.51%
3 Years-22.22%
TTM105.26%
Return on Capital
10 Years0.72%
5 Years2.82%
3 Years1.07%
Last Year2.79%
PCRX Recent Earnings
Pacira BioSciences, Inc. (PCRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
Apr 30, 2026EPS
$0.60
Est $0.55
+9.5%
Revenue
$177M
Est $172M
+3.2%
Q1 2026
Feb 26, 2026EPS
$0.57
Est $0.85
-32.9%
Revenue
$197M
Est $200M
-1.7%
Q4 2025
Nov 6, 2025EPS
$0.70
Est $0.65
+7.7%
Revenue
$180M
Est $202M
-11.1%
Q3 2025
Aug 5, 2025EPS
$0.74
Est $0.72
+2.8%
Revenue
$181M
Est $182M
-0.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.60vs $0.55+9.5% | $177Mvs $172M+3.2% |
| Q1 2026 | Feb 26, 2026 | $0.57vs $0.85-32.9% | $197Mvs $200M-1.7% |
| Q4 2025 | Nov 6, 2025 | $0.70vs $0.65+7.7% | $180Mvs $202M-11.1% |
| Q3 2025 | Aug 5, 2025 | $0.74vs $0.72+2.8% | $181Mvs $182M-0.7% |
Based on last 12 quarters of dataView full earnings history →
PCRX Peer Comparison
Pacira BioSciences, Inc. (PCRX) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 BHC | 2.11B | 5.65 | 13.14 | 8.53% | -11.27% | 5.88% | 56.36 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 |
Compare PCRX vs Peers
Pacira BioSciences, Inc. (PCRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PCRX Income Statement
Pacira BioSciences, Inc. (PCRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 286.63M | 337.28M | 421.03M | 429.65M | 541.53M | 666.82M | 674.98M | 700.97M | 726.41M | 734.86M |
| Revenue Growth % | 3.71% | 17.67% | 24.83% | 2.05% | 26.04% | 23.14% | 1.22% | 3.85% | 3.63% | 4.57% |
| Cost of Goods Sold | 87.92M | 86.84M | 106.71M | 117.33M | 140.25M | 199.29M | 184.67M | 170.43M | 149.75M | 115.44M |
| COGS % of Revenue | 30.67% | 25.75% | 25.35% | 27.31% | 25.9% | 29.89% | 27.36% | 24.31% | 20.61% | - |
| Gross Profit | 198.72M▲ 0% | 250.43M▲ 26.0% | 314.31M▲ 25.5% | 312.32M▼ 0.6% | 401.28M▲ 28.5% | 467.53M▲ 16.5% | 490.31M▲ 4.9% | 530.54M▲ 8.2% | 576.66M▲ 8.7% | 442.05M▲ 0% |
| Gross Margin % | 69.33% | 74.25% | 74.65% | 72.69% | 74.1% | 70.11% | 72.64% | 75.69% | 79.39% | 60.15% |
| Gross Profit Growth % | 19.52% | 26.03% | 25.51% | -0.63% | 28.48% | 16.51% | 4.87% | 8.2% | 8.69% | - |
| Operating Expenses | 218.78M | 232.95M | 303.83M | 265.97M | 311.35M | 407.5M | 402.63M | 603.91M | 543.36M | 594.47M |
| OpEx % of Revenue | 76.33% | 69.07% | 72.17% | 61.9% | 57.49% | 61.11% | 59.65% | 86.15% | 74.8% | - |
| Selling, General & Admin | 161.49M | 177.26M | 200.78M | 193.52M | 199.34M | 254.52M | 269.44M | 294.1M | 368.76M | 375.93M |
| SG&A % of Revenue | 56.34% | 52.56% | 47.69% | 45.04% | 36.81% | 38.17% | 39.92% | 41.96% | 50.76% | - |
| Research & Development | 57.29M | 55.69M | 72.12M | 59.42M | 55.55M | 84.8M | 76.26M | 81.58M | 117.31M | 119.69M |
| R&D % of Revenue | 19.99% | 16.51% | 17.13% | 13.83% | 10.26% | 12.72% | 11.3% | 11.64% | 16.15% | - |
| Other Operating Expenses | 167K | -888K | 30.93M | 13.03M | 56.46M | 68.19M | 56.94M | 228.23M | 57.29M | 4M |
| Operating Income | -24.94M▲ 0% | 15.91M▲ 163.8% | 10.48M▼ 34.2% | 46.35M▲ 342.3% | 89.92M▲ 94.0% | 60.02M▼ 33.3% | 87.67M▲ 46.1% | -73.37M▼ 183.7% | 33.3M▲ 145.4% | 24.95M▲ 0% |
| Operating Margin % | -8.7% | 4.72% | 2.49% | 10.79% | 16.61% | 9% | 12.99% | -10.47% | 4.58% | 3.4% |
| Operating Income Growth % | 22.13% | 163.82% | -34.15% | 342.27% | 94.01% | -33.25% | 46.07% | -183.69% | 145.39% | - |
| EBITDA | -11.1M | 29.08M | 30.06M | 66.26M | 118.47M | 151.53M | 163.25M | 5.41M | 124.33M | 94.81M |
| EBITDA Margin % | -3.87% | 8.62% | 7.14% | 15.42% | 21.88% | 22.72% | 24.19% | 0.77% | 17.12% | 12.9% |
| EBITDA Growth % | 41.88% | 361.89% | 3.36% | 120.45% | 78.8% | 27.9% | 7.74% | -96.68% | 2196.38% | 3192.27% |
| D&A (Non-Cash Add-back) | 13.83M | 13.16M | 19.58M | 19.91M | 28.55M | 91.5M | 75.57M | 78.78M | 91.02M | 69.86M |
| EBIT | -25.8M | 19.89M | 11.17M | 43.6M | 85.4M | 48.88M | 79.01M | -49.67M | 31.48M | 19.04M |
| Net Interest Income | -13.97M | -15.45M | -16.25M | -21.04M | -28.1M | -31.03M | -5.87M | 3.12M | 8.13M | 4.12M |
| Interest Income | 4.08M | 6.5M | 7.38M | 4.63M | 896K | 4.54M | 11.44M | 19.69M | 22.73M | 17.77M |
| Interest Expense | 18.05M | 21.95M | 23.63M | 25.67M | 29M | 35.58M | 17.31M | 16.57M | 14.61M | 8.02M |
| Other Income/Expense | -17.53M | -16.34M | -21.23M | -26.26M | -33.52M | -46.72M | -25.97M | 10.27M | -16.43M | -11.79M |
| Pretax Income | -42.47M▲ 0% | -425K▲ 99.0% | -10.75M▼ 2428.9% | 20.09M▲ 286.9% | 56.4M▲ 180.8% | 13.3M▼ 76.4% | 61.7M▲ 363.8% | -63.11M▼ 202.3% | 16.87M▲ 126.7% | 13.17M▲ 0% |
| Pretax Margin % | -14.82% | -0.13% | -2.55% | 4.68% | 10.42% | 1.99% | 9.14% | -9% | 2.32% | 1.79% |
| Income Tax | 140K | 46K | 268K | -125.43M | 14.42M | -2.61M | 19.75M | 36.45M | 9.84M | 3.86M |
| Effective Tax Rate % | -0.33% | -10.82% | -2.49% | -624.39% | 25.57% | -19.6% | 32% | -57.77% | 58.31% | 29.35% |
| Net Income | -42.61M▲ 0% | -471K▲ 98.9% | -11.02M▼ 2238.9% | 145.52M▲ 1421.0% | 41.98M▼ 71.2% | 15.91M▼ 62.1% | 41.95M▲ 163.7% | -99.56M▼ 337.3% | 7.03M▲ 107.1% | 9.3M▲ 0% |
| Net Margin % | -14.87% | -0.14% | -2.62% | 33.87% | 7.75% | 2.39% | 6.22% | -14.2% | 0.97% | 1.27% |
| Net Income Growth % | -12.28% | 98.89% | -2238.85% | 1421.01% | -71.15% | -62.1% | 163.72% | -337.3% | 107.07% | 108.97% |
| Net Income (Continuing) | -42.61M | -471K | -11.02M | 145.52M | 41.98M | 15.91M | 41.95M | -99.56M | 7.03M | 9.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.07▲ 0% | -0.01▲ 98.9% | -0.27▼ 2247.8% | 3.33▲ 1333.3% | 0.92▼ 72.4% | 0.34▼ 63.0% | 0.89▲ 161.8% | -2.15▼ 341.6% | 0.16▲ 107.4% | 0.23▲ 0% |
| EPS Growth % | -4.9% | 98.93% | -2247.83% | 1333.33% | -72.37% | -63.04% | 161.76% | -341.57% | 107.44% | 105.26% |
| EPS (Basic) | -1.07 | -0.01 | -0.27 | 3.41 | 0.95 | 0.35 | 0.91 | -2.15 | 0.16 | - |
| Diluted Shares Outstanding | 39.81M | 40.91M | 41.51M | 43.68M | 45.63M | 46.54M | 51.98M | 46.24M | 45.04M | 40.91M |
| Basic Shares Outstanding | 39.81M | 40.91M | 41.51M | 42.67M | 44.26M | 45.52M | 46.22M | 46.24M | 44.57M | 40.46M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PCRX Balance Sheet
Pacira BioSciences, Inc. (PCRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 391.11M | 477.97M | 408.56M | 651.62M | 866.05M | 498.33M | 509.99M | 745.13M | 547.97M | 514.96M |
| Cash & Short-Term Investments | 311.35M | 383.45M | 291.95M | 521.66M | 656.41M | 288.65M | 278.58M | 484.62M | 238.42M | 144.31M |
| Cash Only | 54.13M | 132.53M | 78.23M | 99.96M | 585.58M | 104.14M | 153.3M | 276.77M | 158.54M | 144.31M |
| Short-Term Investments | 257.22M | 250.93M | 213.72M | 421.7M | 70.83M | 184.51M | 125.28M | 207.84M | 79.88M | 0 |
| Accounts Receivable | 31.66M | 38M | 47.53M | 53.05M | 96.32M | 98.4M | 105.56M | 113.3M | 124.07M | 125.64M |
| Days Sales Outstanding | 40.31 | 41.12 | 41.21 | 45.06 | 64.92 | 53.86 | 57.08 | 59 | 62.34 | 59.55 |
| Inventory | 41.41M | 48.57M | 58.3M | 64.65M | 98.55M | 96.06M | 104.35M | 125.28M | 152.86M | 150.37M |
| Days Inventory Outstanding | 171.93 | 204.13 | 199.4 | 201.12 | 256.47 | 175.94 | 206.25 | 268.31 | 372.59 | 481.43 |
| Other Current Assets | 6.69M | 7.95M | 0 | 0 | 0 | 15.22M | 21.5M | 21.93M | 32.62M | 94.65M |
| Total Non-Current Assets | 237.26M | 211.38M | 422.51M | 622.89M | 1.21B | 1.18B | 1.06B | 808.39M | 716.94M | 693.57M |
| Property, Plant & Equipment | 107.05M | 108.67M | 142.81M | 211.18M | 264.81M | 254.39M | 234.95M | 216.39M | 182.47M | 175.69M |
| Fixed Asset Turnover | 2.68x | 3.10x | 2.95x | 2.03x | 2.04x | 2.62x | 2.87x | 3.24x | 3.98x | 3.91x |
| Goodwill | 55.2M | 62.04M | 99.55M | 99.55M | 145.18M | 163.24M | 163.24M | 0 | 20.21M | 19.77M |
| Intangible Assets | 0 | 0 | 104.39M | 96.52M | 623.97M | 540.55M | 483.26M | 425.97M | 368.1M | 353.23M |
| Long-Term Investments | 74.19M | 40.02M | 64.8M | 95.46M | 0 | 37.21M | 2.41M | 29.45M | 0 | 41.58M |
| Other Non-Current Assets | 825K | 657K | 10.97M | 14.02M | 21.99M | 27.17M | 36.05M | 6.2M | 22.31M | 42.58M |
| Total Assets | 628.37M▲ 0% | 689.35M▲ 9.7% | 831.07M▲ 20.6% | 1.27B▲ 53.4% | 2.08B▲ 62.8% | 1.68B▼ 19.0% | 1.57B▼ 6.4% | 1.55B▼ 1.3% | 1.26B▼ 18.6% | 1.21B▲ 0% |
| Asset Turnover | 0.46x | 0.49x | 0.51x | 0.34x | 0.26x | 0.40x | 0.43x | 0.45x | 0.57x | 0.55x |
| Asset Growth % | 60.52% | 9.7% | 20.56% | 53.36% | 62.83% | -18.99% | -6.35% | -1.33% | -18.58% | -63.79% |
| Total Current Liabilities | 56.22M | 60.66M | 107.67M | 253.33M | 521.12M | 147.77M | 97.38M | 309.92M | 120.59M | 108.79M |
| Accounts Payable | 14.66M | 14.37M | 12.8M | 10.43M | 10.54M | 15.22M | 15.7M | 19.13M | 15.15M | 14.01M |
| Days Payables Outstanding | 60.86 | 60.39 | 43.78 | 32.45 | 27.44 | 27.87 | 31.03 | 40.98 | 36.93 | 60.84 |
| Short-Term Debt | 324K | 338K | 0 | 149.65M | 374.7M | 33.65M | 8.64M | 201.78M | 9.84M | 9.82M |
| Deferred Revenue (Current) | 102K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 28.76M | 1.62M | 40.44M | 36.94M | 45.49M | 26.2M | 42.56M | 28.81M | 95.6M | 84.96M |
| Current Ratio | 6.96x | 7.88x | 3.79x | 2.57x | 1.66x | 3.37x | 5.24x | 2.40x | 4.54x | 4.54x |
| Quick Ratio | 6.22x | 7.08x | 3.25x | 2.32x | 1.47x | 2.72x | 4.17x | 2.00x | 3.28x | 3.28x |
| Cash Conversion Cycle | 151.39 | 184.87 | 196.82 | 213.74 | 293.95 | 201.92 | 232.31 | 286.33 | 398 | 480.14 |
| Total Non-Current Liabilities | 292.67M | 307.47M | 368.45M | 401.5M | 823.83M | 758.42M | 606.87M | 465.25M | 451.22M | 445.85M |
| Long-Term Debt | 276.17M | 290.59M | 306.05M | 313.03M | 674.53M | 655.82M | 513.8M | 383.55M | 408.37M | 0 |
| Capital Lease Obligations | 0 | 0 | 40.94M | 71.03M | 71.73M | 64.8M | 54.81M | 44.65M | 36.18M | 116.31M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.21M | 17.48M |
| Other Non-Current Liabilities | 16.5M | 16.87M | 21.46M | 17.44M | 67.44M | 37.79M | 38.27M | 37.06M | 2.46M | 529.72M |
| Total Liabilities | 348.89M | 368.13M | 476.12M | 654.83M | 1.34B | 906.19M | 704.26M | 775.17M | 571.81M | 554.64M |
| Total Debt | 276.5M | 290.93M | 351.92M | 541.13M | 1.13B | 763.39M | 586.04M | 638.85M | 454.38M | 9.82M |
| Net Debt | 222.37M | 158.4M | 273.69M | 441.17M | 543.27M | 659.25M | 432.75M | 362.08M | 295.83M | -134.49M |
| Debt / Equity | 0.99x | 0.91x | 0.99x | 0.87x | 1.55x | 0.99x | 0.67x | 0.82x | 0.66x | 0.66x |
| Debt / EBITDA | - | 10.00x | 11.71x | 8.17x | 9.53x | 5.04x | 3.59x | 118.00x | 3.65x | 0.10x |
| Net Debt / EBITDA | - | 5.45x | 9.11x | 6.66x | 4.59x | 4.35x | 2.65x | 66.88x | 2.38x | 2.38x |
| Interest Coverage | -1.43x | 0.91x | 0.47x | 1.70x | 2.95x | 1.37x | 4.56x | -3.00x | 2.16x | 2.37x |
| Total Equity | 279.48M▲ 0% | 321.23M▲ 14.9% | 354.94M▲ 10.5% | 619.69M▲ 74.6% | 730.41M▲ 17.9% | 775.01M▲ 6.1% | 870.13M▲ 12.3% | 778.35M▼ 10.5% | 693.11M▼ 11.0% | 653.89M▲ 0% |
| Equity Growth % | 27.63% | 14.94% | 10.5% | 74.59% | 17.87% | 6.11% | 12.27% | -10.55% | -10.95% | -45.87% |
| Book Value per Share | 7.02 | 7.85 | 8.55 | 14.19 | 16.01 | 16.65 | 16.74 | 16.83 | 15.39 | 15.98 |
| Total Shareholders' Equity | 279.48M | 321.23M | 354.94M | 619.69M | 730.41M | 775.01M | 870.13M | 778.35M | 693.11M | 653.89M |
| Common Stock | 41K | 41K | 42K | 44K | 45K | 46K | 46K | 47K | 48K | 48K |
| Retained Earnings | -389.14M | -388.23M | -399.4M | -253.88M | -211.9M | -148.75M | -106.8M | -206.36M | -199.32M | -196.41M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -25.12M | -176.56M | 0 |
| Accumulated OCI | -454K | -280K | 322K | 318K | 167K | -380K | 247K | 343K | 4.33M | 3.46M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PCRX Cash Flow Statement
Pacira BioSciences, Inc. (PCRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 17.79M | 48.87M | 70.52M | 77.03M | 125.72M | 145.27M | 154.65M | 189.39M | 151.99M | 151.99M |
| Operating CF Margin % | 6.2% | 14.49% | 16.75% | 17.93% | 23.21% | 21.79% | 22.91% | 27.02% | 20.92% | - |
| Operating CF Growth % | -46.84% | 174.78% | 44.3% | 9.23% | 63.2% | 15.56% | 6.45% | 22.46% | -19.75% | -60.33% |
| Net Income | -42.61M | -471K | -11.02M | 145.52M | 41.98M | 15.91M | 41.95M | -99.56M | 7.03M | 9.3M |
| Depreciation & Amortization | 13.83M | 13.16M | 19.58M | 19.91M | 28.55M | 91.5M | 75.57M | 78.78M | 91.02M | 91.19M |
| Stock-Based Compensation | 31.6M | 31.73M | 33.65M | 39.92M | 42.25M | 48.09M | 47.9M | 51.17M | 57.5M | 56.49M |
| Deferred Taxes | 5.87M | 919K | -1.83M | -126.61M | 10.87M | -7.95M | 15.62M | 20.62M | 6.48M | 6.81M |
| Other Non-Cash Items | 11.67M | 14.39M | 37.08M | 22.68M | 20.75M | 14.15M | 19.39M | 156.89M | 28.22M | 23.97M |
| Working Capital Changes | -2.57M | -10.86M | -6.94M | -24.39M | -18.67M | -16.43M | -45.78M | -18.52M | -38.27M | -41.38M |
| Change in Receivables | -1.72M | -6M | -8.52M | -5.52M | -10.43M | -2.08M | -7.16M | -7.75M | -10.74M | -20.87M |
| Change in Inventory | -10.13M | -7.16M | -8.03M | -6.35M | -4.47M | 2.49M | -8.29M | -20.93M | -27.57M | -16.6M |
| Change in Payables | 12.84M | -573K | -1.82M | -3.31M | -10.26M | 6.27M | 916K | 3.08M | -5.6M | -9M |
| Cash from Investing | -223.76M | 20.58M | -128.49M | -277.61M | -20.79M | -225.19M | 77.54M | -83.28M | 99.48M | 144.55M |
| Capital Expenditures | -19.27M | -14.51M | -10.16M | -37.8M | -45.87M | -30.08M | -15.16M | -10.64M | -15.33M | -9.51M |
| CapEx % of Revenue | 6.72% | 4.3% | 2.41% | 8.8% | 8.47% | 4.51% | 2.25% | 1.52% | 2.11% | - |
| Acquisitions | -15M | -7M | -119.31M | 0 | -420.04M | 0 | 0 | 0 | -16.7M | -335K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -8.46M | 157K | 0 | 0 | -4M | -32M | 0 | 0 | 4.93M | 4.93M |
| Cash from Financing | 224.16M | 8.95M | 3.67M | 222.3M | 380.69M | -401.53M | -183.03M | 17.36M | -369.63M | -426.03M |
| Debt Issued (Net) | 226.81M | 0 | -338K | 192.62M | 363.75M | -427.69M | -180.76M | 76.61M | -218.99M | -218.97M |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 27.34M | -106K | -25M | -145.03M | -199.43M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -106K | -25M | -148.33M | -198.37M |
| Other Financing | -2.65M | 8.95M | 4.01M | 29.69M | 16.94M | -1.18M | -2.16M | -34.25M | -5.62M | -7.63M |
| Net Change in Cash | 18.18M▲ 0% | 78.4M▲ 331.2% | -54.3M▼ 169.3% | 21.73M▲ 140.0% | 485.62M▲ 2134.9% | -481.44M▼ 199.1% | 49.16M▲ 110.2% | 123.48M▲ 151.2% | -118.23M▼ 195.8% | -139.3M▲ 0% |
| Free Cash Flow | -1.48M▲ 0% | 34.36M▲ 2419.8% | 60.36M▲ 75.7% | 39.23M▼ 35.0% | 79.85M▲ 103.5% | 115.2M▲ 44.3% | 139.49M▲ 21.1% | 178.75M▲ 28.1% | 136.66M▼ 23.5% | 132.71M▲ 0% |
| FCF Margin % | -0.52% | 10.19% | 14.34% | 9.13% | 14.75% | 17.28% | 20.67% | 25.5% | 18.81% | 18.06% |
| FCF Growth % | -116.94% | 2419.78% | 75.69% | -35.01% | 103.54% | 44.27% | 21.09% | 28.15% | -23.55% | -16.75% |
| FCF per Share | -0.04 | 0.84 | 1.45 | 0.90 | 1.75 | 2.48 | 2.68 | 3.87 | 3.03 | 3.03 |
| FCF Conversion (FCF/Net Income) | -0.42x | -103.76x | -6.40x | 0.53x | 2.99x | 9.13x | 3.69x | -1.90x | 21.61x | 14.27x |
| Interest Paid | 6.9M | 8.21M | 8.2M | 7.21M | 7M | 0 | 27.64M | 15.42M | 0 | 7.67M |
| Taxes Paid | 129K | 128K | 863K | 2.42M | 3.22M | 0 | 4.37M | 11.02M | 0 | 8.66M |
PCRX Key Ratios
Pacira BioSciences, Inc. (PCRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -17.1% | -0.16% | -3.26% | 29.86% | 6.22% | 2.11% | 5.1% | -12.08% | 0.96% | 1.31% |
| Return on Invested Capital (ROIC) | -4.71% | 2.43% | 1.42% | 4.12% | 5.78% | 3.32% | 4.8% | -4.5% | 2.35% | 2.35% |
| Gross Margin | 69.33% | 74.25% | 74.65% | 72.69% | 74.1% | 70.11% | 72.64% | 75.69% | 79.39% | 60.15% |
| Net Margin | -14.87% | -0.14% | -2.62% | 33.87% | 7.75% | 2.39% | 6.22% | -14.2% | 0.97% | 1.27% |
| Debt / Equity | 0.99x | 0.91x | 0.99x | 0.87x | 1.55x | 0.99x | 0.67x | 0.82x | 0.66x | 0.66x |
| Interest Coverage | -1.43x | 0.91x | 0.47x | 1.70x | 2.95x | 1.37x | 4.56x | -3.00x | 2.16x | 2.37x |
| FCF Conversion | -0.42x | -103.76x | -6.40x | 0.53x | 2.99x | 9.13x | 3.69x | -1.90x | 21.61x | 14.27x |
| Revenue Growth | 3.71% | 17.67% | 24.83% | 2.05% | 26.04% | 23.14% | 1.22% | 3.85% | 3.63% | 4.57% |
PCRX SEC Filings & Documents
Pacira BioSciences, Inc. (PCRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
PCRX Frequently Asked Questions
Pacira BioSciences, Inc. (PCRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pacira BioSciences, Inc. (PCRX) reported $734.9M in revenue for fiscal year 2025. This represents a 5177% increase from $13.9M in 2008.
Pacira BioSciences, Inc. (PCRX) grew revenue by 3.6% over the past year. Growth has been modest.
Yes, Pacira BioSciences, Inc. (PCRX) is profitable, generating $9.3M in net income for fiscal year 2025 (1.0% net margin).
Dividend & Returns
Pacira BioSciences, Inc. (PCRX) has a return on equity (ROE) of 1.0%. This is below average, suggesting room for improvement.
Pacira BioSciences, Inc. (PCRX) generated $132.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More PCRX
Pacira BioSciences, Inc. (PCRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates